AAPL   322.43 (-0.83%)
MSFT   183.74 (-0.87%)
FB   226.98 (-1.38%)
GOOGL   1,419.84 (-1.35%)
AMZN   2,467.32 (-0.45%)
BABA   218.64 (+0.01%)
MU   51.25 (+4.76%)
GE   7.58 (+2.85%)
TSLA   871.74 (-1.27%)
AMD   52.37 (-0.68%)
T   31.56 (+0.13%)
GILD   77.64 (+4.35%)
DIS   123.43 (+1.02%)
NFLX   414.12 (-1.86%)
BAC   26.49 (+1.92%)
BA   185.26 (+6.99%)
AAPL   322.43 (-0.83%)
MSFT   183.74 (-0.87%)
FB   226.98 (-1.38%)
GOOGL   1,419.84 (-1.35%)
AMZN   2,467.32 (-0.45%)
BABA   218.64 (+0.01%)
MU   51.25 (+4.76%)
GE   7.58 (+2.85%)
TSLA   871.74 (-1.27%)
AMD   52.37 (-0.68%)
T   31.56 (+0.13%)
GILD   77.64 (+4.35%)
DIS   123.43 (+1.02%)
NFLX   414.12 (-1.86%)
BAC   26.49 (+1.92%)
BA   185.26 (+6.99%)
AAPL   322.43 (-0.83%)
MSFT   183.74 (-0.87%)
FB   226.98 (-1.38%)
GOOGL   1,419.84 (-1.35%)
AMZN   2,467.32 (-0.45%)
BABA   218.64 (+0.01%)
MU   51.25 (+4.76%)
GE   7.58 (+2.85%)
TSLA   871.74 (-1.27%)
AMD   52.37 (-0.68%)
T   31.56 (+0.13%)
GILD   77.64 (+4.35%)
DIS   123.43 (+1.02%)
NFLX   414.12 (-1.86%)
BAC   26.49 (+1.92%)
BA   185.26 (+6.99%)
AAPL   322.43 (-0.83%)
MSFT   183.74 (-0.87%)
FB   226.98 (-1.38%)
GOOGL   1,419.84 (-1.35%)
AMZN   2,467.32 (-0.45%)
BABA   218.64 (+0.01%)
MU   51.25 (+4.76%)
GE   7.58 (+2.85%)
TSLA   871.74 (-1.27%)
AMD   52.37 (-0.68%)
T   31.56 (+0.13%)
GILD   77.64 (+4.35%)
DIS   123.43 (+1.02%)
NFLX   414.12 (-1.86%)
BAC   26.49 (+1.92%)
BA   185.26 (+6.99%)
Log in

NASDAQ:CXRXConcordia International Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.19
MA: $0.19
$0.19
52-Week Range N/A
Volume648,890 shs
Average Volume267,843 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Read More
Concordia International logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CXRX
CUSIPN/A
Phone905-842-5150

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive CXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CXRX and its competitors with MarketBeat's FREE daily newsletter.

Concordia International (NASDAQ:CXRX) Frequently Asked Questions

How were Concordia International's earnings last quarter?

Concordia International Corp (NASDAQ:CXRX) posted its quarterly earnings results on Friday, August, 12th. The company reported $1.38 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $1.38. The business earned $231.70 million during the quarter, compared to the consensus estimate of $229.76 million. The business's revenue for the quarter was up 208.1% on a year-over-year basis. View Concordia International's earnings history.

Has Concordia International been receiving favorable news coverage?

Media coverage about CXRX stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concordia International earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutConcordia International.

Who are some of Concordia International's key competitors?

What other stocks do shareholders of Concordia International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concordia International investors own include Intact Financial (IFC), Constellation Software (CSU), Concordia International (CXR), Hudbay Minerals (HBM), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), First Quantum Minerals (FM), Lundin Mining (LUN), AbbVie (ABBV) and Teck Resources (TECK).

Who are Concordia International's key executives?

Concordia International's management team includes the following people:
  • Mr. Allan Oberman, CEO & Director (Age 60)
  • Mr. Francesco Tallarico, Chief Legal Officer & Sec. (Age 35)
  • Mr. Adrian A. de Saldanha, Exec. (Age 57)
  • Mr. Adeel Ahmad, Chief Financial Officer of Concordia International Segment (Age 44)
  • H.R.H. David J. Price, Chief Financial Officer (Age 55)

What is Concordia International's stock symbol?

Concordia International trades on the NASDAQ under the ticker symbol "CXRX."

What is Concordia International's official website?

The official website for Concordia International is www.concordiarx.com.

How can I contact Concordia International?

Concordia International's mailing address is 277 LAKESHORE RD. E. SUITE 302, OAKVILLE A6, L6J1H9. The company can be reached via phone at 905-842-5150 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.